227 related articles for article (PubMed ID: 35144798)
1. Racial and ethnic enrollment disparities in clinical trials of poly(ADP-ribose) polymerase inhibitors for gynecologic cancers.
Wagar MK; Mojdehbakhsh RP; Godecker A; Rice LW; Barroilhet L
Gynecol Oncol; 2022 Apr; 165(1):49-52. PubMed ID: 35144798
[TBL] [Abstract][Full Text] [Related]
2. Racial and Ethnic Disparities in Clinical Trial Enrollment Among Women With Gynecologic Cancer.
Khadraoui W; Meade CE; Backes FJ; Felix AS
JAMA Netw Open; 2023 Dec; 6(12):e2346494. PubMed ID: 38060227
[TBL] [Abstract][Full Text] [Related]
3. Enrollment of Individuals From Racial and Ethnic Minority Groups in Gynecologic Cancer Precision Oncology Trials.
Mattei LH; Robb L; Banning K; Polan RM; Cote ML
Obstet Gynecol; 2022 Oct; 140(4):654-661. PubMed ID: 36075065
[TBL] [Abstract][Full Text] [Related]
4. An attempt to establish real-world databases of poly(ADP-ribose) polymerase inhibitors for advanced or recurrent epithelial ovarian cancer: the Japanese Gynecologic Oncology Group.
Shimada M; Yoshihara K; Tanigawa T; Nomura H; Hamanishi J; Fujiwara S; Tanabe H; Kajiyama H; Mandai M; Aoki D; Enomoto T; Okamoto A
J Gynecol Oncol; 2023 May; 34(3):e62. PubMed ID: 37116954
[TBL] [Abstract][Full Text] [Related]
5. Racial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trials.
Hantel A; Luskin MR; Garcia JS; Stock W; DeAngelo DJ; Abel GA
Blood Adv; 2021 Nov; 5(21):4352-4360. PubMed ID: 34473244
[TBL] [Abstract][Full Text] [Related]
6. Disparities in the Inclusion of Racial and Ethnic Minority Groups and Older Adults in Prostate Cancer Clinical Trials: A Meta-analysis.
Riaz IB; Islam M; Ikram W; Naqvi SAA; Maqsood H; Saleem Y; Riaz A; Ravi P; Wang Z; Hussain SA; Warner JL; Odedina FT; Duma N; Singh P; Kehl KL; Kamran SC; Murad MH; Landman A; Van Allen E; Bryce AH
JAMA Oncol; 2023 Feb; 9(2):180-187. PubMed ID: 36416812
[TBL] [Abstract][Full Text] [Related]
7. Clinical Trial Racial and Ethnic Disparities in Minimally Invasive Gynecologic Surgery.
Sweterlitsch KM; Meyer R; Ohayon A; Levin G; Hamilton K; Truong M; Wright KN; Siedhoff MT
J Minim Invasive Gynecol; 2024 May; 31(5):414-422. PubMed ID: 38325584
[TBL] [Abstract][Full Text] [Related]
8. Racial and Ethnic Distribution in Diabetic Macular Edema Clinical Trials in the United States (2002-2021).
Yu AJ; Masalkhi M; Brown R; Chen B; Chhablani J
Ophthalmol Retina; 2023 Dec; 7(12):1035-1041. PubMed ID: 37479084
[TBL] [Abstract][Full Text] [Related]
9. Variation in Breast Cancer Subtype Incidence and Distribution by Race/Ethnicity in the United States From 2010 to 2015.
Kong X; Liu Z; Cheng R; Sun L; Huang S; Fang Y; Wang J
JAMA Netw Open; 2020 Oct; 3(10):e2020303. PubMed ID: 33074325
[TBL] [Abstract][Full Text] [Related]
10. Underrepresentation of racial and ethnic minority groups in gynecologic oncology: An analysis of over 250 trials.
Richardson MT; Barry D; Steinberg JR; Thirunavu V; Strom DE; Holder K; Zhang N; Turner BE; Magnani CJ; Weeks BT; Young AMP; Lu CF; Wolgemuth TR; Laasiri N; Squires NA; Anderson JN; Karlan BY; Chan JK; Kapp DS; Roque DR; Salani R
Gynecol Oncol; 2024 Feb; 181():1-7. PubMed ID: 38096673
[TBL] [Abstract][Full Text] [Related]
11. Diversity and transparency in gynecologic oncology clinical trials.
Montes de Oca MK; Howell EP; Spinosa D; Knochenhauer H; Peipert BJ; Severson E; Ramkissoon S; Akinyemiju TF; Previs RA
Cancer Causes Control; 2023 Feb; 34(2):133-140. PubMed ID: 36284031
[TBL] [Abstract][Full Text] [Related]
12. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
13. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Wiggans AJ; Cass GK; Bryant A; Lawrie TA; Morrison J
Cochrane Database Syst Rev; 2015 May; 2015(5):CD007929. PubMed ID: 25991068
[TBL] [Abstract][Full Text] [Related]
14. Racial and Ethnic Disparities in Primary Open-Angle Glaucoma Clinical Trials: A Systematic Review and Meta-analysis.
Allison K; Patel DG; Greene L
JAMA Netw Open; 2021 May; 4(5):e218348. PubMed ID: 34003274
[TBL] [Abstract][Full Text] [Related]
15. Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Kerliu L; Myruski S; Bhatti A; Soni P; Petrosius P; Pervanas HC; Horton ER
Ann Pharmacother; 2020 Oct; 54(10):1010-1015. PubMed ID: 32172572
[TBL] [Abstract][Full Text] [Related]
16. Characterizing participants in the North Carolina Breast and Cervical Cancer Control Program: A retrospective review of 90,000 women.
Tait SD; Ren Y; Horton CC; Oshima SM; Thomas SM; Wright S; Caesar A; Plichta JK; Hwang ES; Greenup RA; Rosenberger LH; DiLalla GD; Menendez CS; Tolnitch L; Hyslop T; Nelson D; Fayanju OM
Cancer; 2021 Jul; 127(14):2515-2524. PubMed ID: 33826758
[TBL] [Abstract][Full Text] [Related]
17. Racial and Ethnic Disparities Among Participants in Precision Oncology Clinical Studies.
Aldrighetti CM; Niemierko A; Van Allen E; Willers H; Kamran SC
JAMA Netw Open; 2021 Nov; 4(11):e2133205. PubMed ID: 34748007
[TBL] [Abstract][Full Text] [Related]
18. Racial and ethnic disparities in incidence and mortality for the five most common gastrointestinal cancers in the United States.
Bui A; Yang L; Soroudi C; May FP
J Natl Med Assoc; 2022 Aug; 114(4):426-429. PubMed ID: 35525822
[TBL] [Abstract][Full Text] [Related]
19. Trends of Ovarian Cancer Incidence by Histotype and Race/Ethnicity in the United States 1992-2019.
Phung MT; Pearce CL; Meza R; Jeon J
Cancer Res Commun; 2023 Jan; 3(1):1-8. PubMed ID: 36968229
[TBL] [Abstract][Full Text] [Related]
20. Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.
Onstad M; Coleman RL; Westin SN
Drugs; 2020 Oct; 80(15):1525-1535. PubMed ID: 32852746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
